|
Androgen deprivation therapy (ADT) Clinical Trials
13 actively recruiting trials across 6 locations
No change since May 2026
Pipeline
Phase 1: 1Phase 2: 7Phase 3: 2Phase 2/3: 2
Top Sponsors
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2
- Affidea Nu-med Center of Oncological DIagnostics and Therapy2
- University of Texas Southwestern Medical Center1
- University of Nebraska1
- University of Chicago1
Indications
- Cancer13
- Prostate Cancer9
- Dose Escalation: Solid Tumors2
- Stereotactic Body Radiation Therapy (SBRT)2
- Biochemical Recurrence2
Other6 trials
Dallas, Texas2 trials
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Mary Crowley Cancer Research
Phase 1
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
UT Southwestern Medical Center-Dallas
Phase 2
Phoenix, Arizona1 trial
Chicago, Illinois1 trial
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
UChicago Medicine Comprehensive Cancer Center
Phase 2
Omaha, Nebraska1 trial
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska Medical Center
Phase 2
New York, New York1 trial
Cleveland, Ohio1 trial
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
University Hospitals Cleveland Medical Center Seidman Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.